Prof. David Anderson

.

biography

Prof David Anderson, PhD, trained in virology and microbiology and has worked in development and commercialisation of point-of-care (POC) diagnostic tests for more than 25 years. At the Burnet Institute he led development of tests including the WHO-Prequalified Visitect CD4 T-cell test and tests for viral hepatitis, liver disease, syphilis and cirrhosis. Since joining Prof Ivo Mueller’s team in 2024 as a Senior Entrepreneur Scientist his major focus has been on novel POC tests for iron deficiency and hepatitis B, and development of new platform technologies for low-cost diagnostics. He is also the co-founder and Chief Scientific Officer of Nanjing DeShi Diagnostic Technology Co., China, an ISO13485:2016-certified manufacturer of lateral flow POC diagnostics

Title

Pushing the boundaries of low-cost, point-of-care diagnostics

abstract

Point of care (POC) diagnostics have been used for decades, initially for pregnancy testing and then applied to many diseases and especially infectious diseases including HIV, malaria, syphilis and of course SARS-CoV-2, expanding diagnostic testing well beyond clinical laboratories and including home tests. However all these tests are qualitative, “Yes/No” tests and there have been few examples of instrument-free, semi-quantitative tests to address disease biomarkers where the amount of the analyte in question falls inside, or outside a normal range. The Visitect CD4 T-cell test introduced a novel, simple method of measuring visual threshold levels for biomarkers in POC tests, and in this talk I will describe our overall approach including CD4 T-cells and liver disease, and our current projects including ferritin and transferrin saturation in iron deficiency.